Very Low Numbers of CD4+  FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model

Allogeneic hematopoietic stem cell transplantation (aHSCT) has been administered as a therapeutic modality for a number of genetic disorders, immune deficiency syndromes, and hematologic diseases and malignancies. These conditions include reconstitution of the lymphoid system in patients with congenital immunodeficiency diseases (eg, SCID), as a vehicle for gene therapy for individuals with enzyme deficiencies (eg, Gaucher's disease), as a tolerance protocol for patients in need of tissue transplants (eg, diabetes, kidney), and as rescue and treatment for patients with sickle cell disease, thalassemias, and hematologic cancers (eg, leukemia, lymphoma).

Source: Biology of Blood and Marrow Transplantation - May 8, 2018 Category: Hematology Authors: Sabrina Copsel, Dietlinde Wolf, Brandon Kale, Henry Barreras, Casey O. Lightbourn, Cameron S. Bader, Warren Alperstein, Norman H. Altman, Krishna V. Komanduri, Robert B. Levy Source Type: research